trial
as of 2026-07-01Bio-equivalence Study Between SAPHRIS and Asenapine
NCTId NCT01948024
at a glance
Phase 1 · Completed
Enrollment 65 (actual)
Sponsored by Sun Pharmaceutical Industries Limited
Primary completion 2013-08
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
65 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2013-07
Primary completion
2013-08
Eligibility
ALL · 18 Years · 80 Years
Interventions & indications
Sponsors
Sun Pharmaceutical Industries LimitedLead Sponsor
bioRASI, LLCCollaborator
Investigators
7
David P Walling, PhDPrincipal Investigator
Robert A Riesenberg, MDPrincipal Investigator
Kurian Abraham, MDPrincipal Investigator
Evagelos Coskinas, MD, PhDPrincipal Investigator
James S. McDonough, MDPrincipal Investigator
Gilbert R. Weiner, DOPrincipal Investigator
Jim G. Aukstuolis, MDPrincipal Investigator
Sites
7 total
Little Rock, United StatesCosta Mesa, United StatesGarden Grove, United StatesLeesburg, United StatesMiami, United StatesAtlanta, United StatesCharlotte, United States
Facts & assertions
4 sourced
Enrollment
65
Phase
PHASE1
Primary Completion Date
2013-08
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
company
indication
investigator
person
person
person